Your browser doesn't support javascript.
loading
Predicting the rising incidence and mortality of endometrial cancers among women aged 65-74 years in Catalonia.
Frias-Gomez, Jon; Peremiquel-Trillas, Paula; Alemany, Laia; Ameijide, Alberto; Marcos-Gragera, Rafael; Ponce, Jordi; Brunet, Joan; Matias-Guiu, Xavier; Galceran, Jaume; Izquierdo, Ángel; Borràs, Josep M; Costas, Laura; Clèries, Ramon.
Affiliation
  • Frias-Gomez J; Cancer Epidemiology Research Programme, Catalan Institute of Oncology, Av Gran Vía 199-203, L'Hospitalet de Llobregat, Barcelona, 08908, Spain; Bellvitge Biomedical Research Institute (IDIBELL), Av Gran Vía 199-203, L'Hospitalet de Llobregat, Barcelona, 08908, Spain; Faculty of Medicine, University
  • Peremiquel-Trillas P; Cancer Epidemiology Research Programme, Catalan Institute of Oncology, Av Gran Vía 199-203, L'Hospitalet de Llobregat, Barcelona, 08908, Spain; Bellvitge Biomedical Research Institute (IDIBELL), Av Gran Vía 199-203, L'Hospitalet de Llobregat, Barcelona, 08908, Spain; Faculty of Medicine, University
  • Alemany L; Cancer Epidemiology Research Programme, Catalan Institute of Oncology, Av Gran Vía 199-203, L'Hospitalet de Llobregat, Barcelona, 08908, Spain; Bellvitge Biomedical Research Institute (IDIBELL), Av Gran Vía 199-203, L'Hospitalet de Llobregat, Barcelona, 08908, Spain; Consortium for Biomedical Resear
  • Ameijide A; Tarragona Cancer Registry, Cancer Prevention and Epidemiology Service, Sant Joan de Reus University Hospital, Reus, Spain; Pere Virgili Health Reserach Institute (IISPV), Reus, Spain.
  • Marcos-Gragera R; Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública - CIBERESP), Carlos III Institute of Health, Avda. Monforte de Lemos 3-5, Madrid, Spain; Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonom
  • Ponce J; Department of Gynecology and Obstetrics, Bellvitge University Hospital, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
  • Brunet J; Medical Sciences Dpt, School of Medicine, University of Girona, Girona, Spain; Hereditary Cancer Program, IDIBELL, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Madrid, Spain; Medical Oncology Department, Cata
  • Matias-Guiu X; Faculty of Medicine, University of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red en Cáncer (CIBERONC), Madrid, Spain; Department of Pathology, Bellvitge University Hospital, IDIBELL. Hospitalet de Llobregat, Barcelona, Spain; Department of Pathology, Arnau de Vilanova Univers
  • Galceran J; Tarragona Cancer Registry, Cancer Prevention and Epidemiology Service, Sant Joan de Reus University Hospital, Reus, Spain; Pere Virgili Health Reserach Institute (IISPV), Reus, Spain.
  • Izquierdo Á; Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Girona, 17007, Spain; Descriptive Epidemiology, Genetics and Cancer Prevention Group, Girona Biomedical Research Institute (IDIBGI), Spai
  • Borràs JM; Bellvitge Biomedical Research Institute (IDIBELL), Av Gran Vía 199-203, L'Hospitalet de Llobregat, Barcelona, 08908, Spain; Cancer Plan, Catalan Institute of Oncology, Av Gran Vía 199-203, L'Hospitalet de Llobregat, Barcelona, 08908, Spain; Department of Clinical Sciences, Faculty of Medicine, Unive
  • Costas L; Cancer Epidemiology Research Programme, Catalan Institute of Oncology, Av Gran Vía 199-203, L'Hospitalet de Llobregat, Barcelona, 08908, Spain; Bellvitge Biomedical Research Institute (IDIBELL), Av Gran Vía 199-203, L'Hospitalet de Llobregat, Barcelona, 08908, Spain. Electronic address: lcostas@icon
  • Clèries R; Bellvitge Biomedical Research Institute (IDIBELL), Av Gran Vía 199-203, L'Hospitalet de Llobregat, Barcelona, 08908, Spain; Cancer Plan, Catalan Institute of Oncology, Av Gran Vía 199-203, L'Hospitalet de Llobregat, Barcelona, 08908, Spain; Department of Clinical Sciences, Faculty of Medicine, Unive
Maturitas ; 144: 11-15, 2021 Feb.
Article in En | MEDLINE | ID: mdl-33358202
ABSTRACT
Endometrial cancer is currently one of the most common gynecological cancers. Reported incidence rates vary in Spain depending on the region. We estimated what the incidence and mortality of endometrial cancers in Catalonia will be by 2030 and compared the predictions with data from 2010. Bayesian autoregressive age-period-cohort models were employed to predict incidence and mortality rates for 2015-2030. The incidence of endometrial cancer for women younger than 65 years was predicted to be lower in 2030 than in 2010, whereas it was predicted to be higher for women aged 65-74 years. Moreover, mortality rates for women aged ≥65 in 2030 are likely to exceed the rates in 2010. Five-year relative survival for all ages was slightly higher in the period 2005-2009 (79.3 %, 95 %CI 75.8 %-82.9 %) compared with those in 1995-1999 (76.0 %, 95 %CI 72.1 %-80.2 %). This plausible new scenario might be useful to plan new clinical and preventive strategies in the near future.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Endometrial Neoplasms Type of study: Incidence_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Middle aged Country/Region as subject: Europa Language: En Journal: Maturitas Year: 2021 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Endometrial Neoplasms Type of study: Incidence_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Middle aged Country/Region as subject: Europa Language: En Journal: Maturitas Year: 2021 Document type: Article